Literature DB >> 16956948

Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infection.

Tara M Riddle1, Norah J Shire, Marc S Sherman, Kelly F Franco, Haynes W Sheppard, Julie A E Nelson.   

Abstract

We examined the rates of variant population turnover of the V1-V2 and V4-V5 hypervariable domains of the human immunodeficiency virus type 1 (HIV-1) gp120 molecule in longitudinal plasma samples from 14 men with chronic HIV-1 infection using heteroduplex tracking assays (HTA). Six men had high rates of CD4+ T-cell loss, and eight men had low rates of CD4+ T-cell loss over 2.5 to 8 years of infection. We found that V1-V2 and V4-V5 env populations changed dramatically over time in all 14 subjects; the changes in these regions were significantly correlated with each another over time. The subjects with rapid CD4 loss had significantly less change in their env populations than the subjects with slow CD4 loss. The two subjects with rapid CD4 loss and sustained low CD4 counts (<150/microl for at least 2 years) showed stabilization of their V1-V2 and V4-V5 populations as reflected by low levels of total change in HTA pattern and low HTA indices (a novel measure of the emergence of new bands and band distribution); this stabilization was not observed in other subjects. The stabilization of env variant populations at low CD4 counts following periods of rapid viral evolution suggests that selective pressure on env, likely from new immune responses, is minimal when CD4 counts drop dramatically and remain low for extended periods of time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956948      PMCID: PMC1641766          DOI: 10.1128/JVI.00644-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Linkage disequilibrium test implies a large effective population number for HIV in vivo.

Authors:  I M Rouzine; J M Coffin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.

Authors:  Peter D Kwong; Michael L Doyle; David J Casper; Claudia Cicala; Stephanie A Leavitt; Shahzad Majeed; Tavis D Steenbeke; Miro Venturi; Irwin Chaiken; Michael Fung; Hermann Katinger; Paul W I H Parren; James Robinson; Donald Van Ryk; Liping Wang; Dennis R Burton; Ernesto Freire; Richard Wyatt; Joseph Sodroski; Wayne A Hendrickson; James Arthos
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

3.  A robust measure of HIV-1 population turnover within chronically infected individuals.

Authors:  G Achaz; S Palmer; M Kearney; F Maldarelli; J W Mellors; J M Coffin; J Wakeley
Journal:  Mol Biol Evol       Date:  2004-06-23       Impact factor: 16.240

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

6.  Influence of random genetic drift on human immunodeficiency virus type 1 env evolution during chronic infection.

Authors:  Daniel Shriner; Raj Shankarappa; Mark A Jensen; David C Nickle; John E Mittler; Joseph B Margolick; James I Mullins
Journal:  Genetics       Date:  2004-03       Impact factor: 4.562

Review 7.  Glycosylation of the ENV spike of primate immunodeficiency viruses and antibody neutralization.

Authors:  Cheryl A Pikora
Journal:  Curr HIV Res       Date:  2004-07       Impact factor: 1.581

8.  Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

Authors:  Kelly Stefano Cole; Jonathan D Steckbeck; Jennifer L Rowles; Ronald C Desrosiers; Ronald C Montelaro
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection.

Authors:  Kathryn M Kitrinos; Noah G Hoffman; Julie A E Nelson; Ronald Swanstrom
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

Authors:  Y Koyanagi; S Miles; R T Mitsuyasu; J E Merrill; H V Vinters; I S Chen
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

View more
  10 in total

1.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

2.  Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection.

Authors:  Patrick R Harrington; Julie A E Nelson; Kathryn M Kitrinos; Ronald Swanstrom
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

3.  CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.

Authors:  Ziyaad Valley-Omar; Sengeziwe Sibeko; Jeffrey Anderson; Sarah Goodier; Lise Werner; Leslie Arney; Vivek Naranbhai; Florette Treurnicht; Melissa-Rose Abrahams; Gama Bandawe; Ronald Swanstrom; Quarraisha Abdool Karim; Salim S Abdool Karim; Carolyn Williamson
Journal:  J Infect Dis       Date:  2012-05-02       Impact factor: 5.226

4.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 5.  Coreceptor use in nonhuman primate models of HIV infection.

Authors:  Silvana Tasca Sina; Wuze Ren; Cecilia Cheng-Mayer
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

6.  Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.

Authors:  Filippo Canducci; Maria Chiara Marinozzi; Michela Sampaolo; Stefano Berrè; Patrizia Bagnarelli; Massimo Degano; Giulia Gallotta; Benedetta Mazzi; Philippe Lemey; Roberto Burioni; Massimo Clementi
Journal:  Retrovirology       Date:  2009-01-15       Impact factor: 4.602

7.  Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.

Authors:  Astrid Gall; Steve Kaye; Stéphane Hué; David Bonsall; Richard Rance; Gregory J Baillie; Sarah J Fidler; Jonathan N Weber; Myra O McClure; Paul Kellam
Journal:  Retrovirology       Date:  2013-01-18       Impact factor: 4.602

8.  Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses.

Authors:  Tamara Nora; Francine Bouchonnet; Béatrice Labrosse; Charlotte Charpentier; Fabrizio Mammano; François Clavel; Allan J Hance
Journal:  Retrovirology       Date:  2008-02-29       Impact factor: 4.602

9.  Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia.

Authors:  Gretja Schnell; Serena Spudich; Patrick Harrington; Richard W Price; Ronald Swanstrom
Journal:  PLoS Pathog       Date:  2009-04-24       Impact factor: 6.823

10.  Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry.

Authors:  Yan Li; Dan Yang; Jia-Ye Wang; Yuan Yao; Wei-Zhe Zhang; Lu-Jing Wang; De-Chun Cheng; Feng-Kun Yang; Feng-Min Zhang; Min Zhuang; Hong Ling
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.